GemPharmatech's Collaboration to Enhance Cancer Therapies
GemPharmatech is taking significant steps in improving cancer treatments through its innovative antibody discovery platform. This advancement aims to fast-track the development of groundbreaking cancer therapies, especially in partnership with renowned institutions in the medical field.
Partnership with Memorial Sloan Kettering Cancer Center
In an exciting development, GemPharmatech has announced a collaboration with the esteemed Memorial Sloan Kettering Cancer Center (MSK) to expedite the discovery of novel therapeutic antibodies. This strategic partnership is set to leverage GemPharmatech's superior preclinical research capabilities and its vast resources.
Under this non-exclusive agreement, MSK researchers will utilize GemPharmatech’s NeoMab® platform. This advanced transgenic mouse model is specifically designed for the rapid and efficient identification of fully human therapeutic antibodies, significantly advancing research in oncology.
Advancing Therapeutic Antibody Research
The collaboration aims to empower MSK scientists, who are already at the forefront of preclinical research, to accelerate the creation of fully human therapeutic antibodies targeting critical areas in cancer treatment. GemPharmatech's innovative approach is focused on addressing urgent unmet needs within oncology.
Dr. Xiang Gao, the founder of GemPharmatech, expressed his enthusiasm about this collaboration, stating, "Our mission has always been to enable transformative biomedical research through innovative mouse models and technologies. Collaborating with MSK on antibody discovery represents a powerful opportunity to combine scientific excellence with cutting-edge mouse models such as NeoMab®. Together, we can accelerate the development of novel therapeutics that address some of the most urgent challenges in cancer treatment." This statement highlights the commitment to bringing impactful therapies to market faster.
NeoMab® Platform's Unique Features
The NeoMab® platform is integrated with part of the largest library of genetically engineered mouse models globally. This immunoglobulin gene-humanized mouse model carries a comprehensive repertoire of human heavy and kappa light chains, enabling a streamlined process for creating high-affinity fully human antibodies. This innovative design is crucial as it allows the rapid generation of antibodies while bypassing extensive humanization sequences.
Transforming Cancer Treatment Approaches
The collaboration reflects a shared goal of expanding potential therapeutic options for cancer patients. The NeoMab® platform is a game-changer as it aims to decrease antibody development timelines while minimizing immunogenicity risks, resulting in enhanced safety profiles for therapeutic candidates.
Dr. Brandy Wilkinson, the Chief Executive Officer of GemPharmatech, stated, "This collaboration underscores our mission to provide the global research community with advanced platforms to accelerate innovations in drug discovery. We are excited to be supporting MSK's pioneering work in oncology research with the NeoMab® platform. It is an honor to contribute to their scientific mission and to help advance antibody programs with the potential to transform therapies and improve patient outcomes worldwide." This shows the dedication of both organizations towards innovation and patient care.
About GemPharmatech
GemPharmatech stands as a leading global contract research organization, offering fully integrated preclinical services built upon the world's most extensive library of genetically engineered mouse models. They provide over 25,000 strains of various genetically modified mice, aiding researchers in accelerating therapeutic innovation across various fields, including oncology, immunology, and neurodegenerative diseases. Apart from these services, GemPharmatech is also known for custom model generation, microbiome research, and associated support services.
Frequently Asked Questions
What is the purpose of the collaboration between GemPharmatech and MSK?
The collaboration aims to accelerate the discovery of new therapeutic antibodies to enhance cancer treatments using advanced mouse models.
What platform is being utilized in this partnership?
The NeoMab® platform, a next-generation transgenic mouse model designed for rapid discovery of fully human therapeutic antibodies, is utilized.
Who is leading GemPharmatech?
Dr. Xiang Gao is the founder of GemPharmatech, leading innovative efforts in preclinical research solutions.
How can GemPharmatech’s services benefit researchers?
Researchers gain access to advanced mouse models and extensive preclinical resources that facilitate rapid and efficient drug discovery.
What other services does GemPharmatech offer?
In addition to preclinical services, GemPharmatech offers custom model generation, microbiome research, and vivarium rental services.
